Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 14 of 16
Feb 14, 2026After a slow uptake period, the partnership between Vertex and CRISPR Therapeutics for Casgevy gene therapy targeting sickle cell disease and beta thalassemia is poised for substantial growth. This reflects the increasing acceptance and accessibility of advanced gene therapies in rare disease management.
Feb 13, 2026The Mayo Clinic Platform offers a revealing perspective on the limitations of de-identified electronic health records (EHR) data, suggesting that extensive de-identification processes may diminish the data's practical value for pharma and research entities. This insight underscores the ongoing tension between patient privacy and the imperative for actionable, high-quality data in drug development.
Feb 12, 2026BridgeBio Pharma's recent clinical trial achievement with infigratinib marks a meaningful advancement in the treatment of achondroplasia. The drug demonstrated significant improvements in growth rates and body composition in children, offering hope to patients with this genetic condition. Regulatory pathways are now anticipated to proceed toward FDA filing within the year.
Feb 11, 2026After an enthusiastic response to its initial data last year, Pelage is now prepared to fully disclose the scientific foundation behind its innovative hair loss candidate. This development marks a significant shift in the approach to hair loss treatments, emphasizing rigorous scientific validation over mere topical solutions.
Feb 5, 2026Veradermics is developing a novel oral formulation of minoxidil, historically a topical treatment for hair loss, leveraging technology intended to reduce systemic side effects. With pivotal trials underway, the company aims to establish an effective and safer alternative for alopecia sufferers, entering a competitive market with significant unmet needs.
Feb 3, 2026As the pandemic winds down, BioNTech and Moderna's once parallel trajectories have diverged significantly. BioNTech’s diversified modality strategy contrasts with Moderna’s mRNA-centric pipeline, highlighting strategic shifts in how these companies leverage their COVID-19 windfalls to fuel future growth.
Feb 1, 2026Tenpoint Therapeutics' Yuvezzi eye drop represents a significant advancement in presbyopia treatment through its dual mechanism of action. This approval not only marks a pivotal milestone for the company but also impacts the competitive landscape of vision therapeutics. Supported by substantial financing, Yuvezzi is poised to reshape how presbyopia is managed clinically.
Jan 29, 2026Recent advancements in genetic research have deepened our understanding of human longevity. This article explores the findings of a pivotal study that redefines the impact of inherited genes on lifespan and discusses implications for aging research and therapeutic strategies.
Jan 28, 2026Phase 2 data reveal Roche's investigational GLP-1 and GIP agonist achieved a 22.5% placebo-adjusted weight loss at 48 weeks. This efficacy supports the advancement to pivotal Phase 3 trials, marking a critical step in the development of new obesity treatment options amid a highly competitive market.
Jan 27, 2026Emerging biotech Baseline Therapeutics is positioning itself as a challenger in the development of GLP-1–based therapies for alcohol use disorder. Their lead asset, BT-001, is set to enter late-stage clinical trials, marking a significant step in tackling addiction through novel mechanisms.
Jan 26, 2026Endometriosis is a painful condition affecting millions, frequently suffering from diagnostic delays due to complex symptoms and limited testing tools. Several biotech companies are now leveraging advances in diagnostics to develop new tests that promise to simplify and accelerate detection, potentially transforming patient outcomes and quality of life.
Jan 26, 2026Accelerating progress in rare disease therapeutics demands innovative strategies beyond traditional frameworks. A sandbox approach that combines robust data analytics with regulatory experimentation offers a promising pathway to address inherent complexities and drive advancement in this difficult field.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.